Precision’s Galante Addresses 21st Century Cures Act and Future Utilization of Real-World Evidence in Clinical Leader
In the latest edition of Clinical Leader, Precision for Value’s Dominic Galante addresses how real-world evidence is being leveraged after the adoption of the 21st Century Cures Act, and provides some next steps for life science companies. (more…)
Hennessey Quoted on Adherence in MM&M
MM&M editor-in-chief Marc Iskowitz quotes Precision’s Maureen Hennessey and cites new findings from Precision for Value’s Rapid Pulse survey in an article examining Otsuka’s new “digital drug” and the continued importance of adherence. (more…)
Precision’s Messerschmidt Discusses New Myeloma Therapies in Managed Healthcare Executive
In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements. (more…)
Precision’s Shafrin Writes of the Value of Real-World Evidence in Drug Discovery & Development
In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it. (more…)
POLITICO Pulses on Launch of IVI’s New Open-Source Value Tool
Must-read morning briefing POLITICO Pulse talks with Innovation & Value Initiative (IVI) executive director Darius Lakdawalla on the launch of a first-of-its-kind open-source project for determining the value of medical treatments. (more…)